knowledge -WSS

knowledge

author：explore 2025-10-01 15:39:34 - browse：48

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Review: 'Barbie' will hit you like a shot in the heart

focus

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Bird flu: Don't repeat Covid's 'health versus the economy' framing

AbbVie dramatically boosts its spending on lobbying

FDA official pushes for dedicated emerging pathogens team

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

FDA official pushes for dedicated emerging pathogens team

explore

knowledge

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Artificial intelligence advances fuel industry trying to preserve loved ones after death

ChatGPT in medicine: STAT answers readers' burning questions

Death toll from an explosion and collapse of a Paris building in June climbs to 3

The cancer drug shortage isn’t new — and neither are the solutions

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Moonlake's readout produced a cash windfall. Risks remain

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Virginia high school admissions case could be legal follow

Data integrity in scientific journals requires "effort" by publishers, institutions

hotspot

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Caitlin Bernard's story shows physicians can't shy from advocacy

Bird flu: Don't repeat Covid's 'health versus the economy' framing

HIV vaccine remains elusive. Immunologists keep trying new ideas

Data integrity in scientific journals requires "effort" by publishers, institutions

Organ transplantation is at a crossroads. Major reform is needed

focus

focus

leisure time

knowledge